THEVAX GENETICS VACCINE CO., LTD.’s "PEK fusion protein technology" is an immunotherapy specifically designed to induce a "cellular immune response." This is an immune response capable of effectively clearing infected or cancerous cells in patients. Targeting different diseases, simply by inserting different antigens into the "PEK fusion protein," it has the potential to become a promising new drug for treating specific diseases. Therefore, the application potential of PEK technology is extremely broad. The first adopter was Reber Genetics, the animal health company of the Sheng Bao Group. Reber Genetics inserted antigens related to Porcine Reproductive and Respiratory Syndrome (PRRS, or blue-ear pig disease) into the PEK fusion protein, creating the PRRSFREE vaccine. This vaccine has already been launched and sold in several countries, validating the feasibility of the PEK technology concept. THEVAX GENETICS VACCINE CO., LTD. has introduced this technology into the field of human disease treatment. To treat conditions including cervical precancerous lesions, relevant antigens were inserted into the PEK fusion protein, leading to the development of the TVGV-1 therapy.
(The content above was translated by AI.)

GenomeFrontier’s product pipeline is built around its Quantum Engine™, which integrates four core platforms: Quantum Nufect™ (gentle, efficient gene delivery), Quantum pBac™ (high-capacity non-viral gene integration), iCellar™ (robust cell expansion), and

Genome editing and cell/stem cell culture technology platforms, and cancer immunotherapy research and development.
(The content above was translated by AI.)

ARD103
ANTI-CLL1 auto-CAR-T
ARD103, our priority product, is an autologous CAR-T cell manufactured by DashCAR® technology with an ultra-fast processing time and stem cell-like phenotypes. ARD103 specifically targeted C-type lectin-like molecule-1 (CLL-1)